Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CKR
|
|||
| Former ID |
DIB010213
|
|||
| Drug Name |
Nabumetone
|
|||
| Synonyms |
NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | |
| Company |
Nobex Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H16O2
|
|||
| Canonical SMILES |
CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
|
|||
| InChI |
1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
|
|||
| InChIKey |
BLXXJMDCKKHMKV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 42924-53-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
866759, 5089100, 7847491, 7980058, 8139968, 8150030, 8152727, 11112767, 11336025, 11361264, 11364380, 11366942, 11369504, 11373826, 11377666, 11462236, 11466937, 11468057, 11485833, 11486693, 11489785, 11491989, 11495300, 12012677, 15196152, 24897772, 26612514, 26679665, 26748824, 26748825, 29223506, 46507729, 47216826, 47515367, 47662339, 47736536, 47885464, 48035181, 49698816, 49896758, 53786809, 56364587, 56422157, 57322259, 57654458, 80932204, 85087976, 85787391, 92124694, 92125724
|
|||
| ChEBI ID |
CHEBI:7443
|
|||
| ADReCS Drug ID | BADD_D01511 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli ATCC 25922
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Resulting Metabolite | 4-(6-methoxy-2-naphthyl)-butan-2-ol | |||
| Metabolic Effect | Decrease activity | |||
| Description | Nabumetone can be metabolized to 4-(6-methoxy-2-naphthyl)-butan-2-ol by Escherichia coli ATCC 25922, which results in the decrease of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4], [5] | |||
| Metabolic Reaction | Carbonyl reduction | |||
| Resulting Metabolite | 4-(6-methoxy-2-naphthyl)-3-hydroxybutan-2-one | |||
| Metabolic Effect | Decrease activity | |||
| Description | Nabumetone can be metabolized to 4-(6-methoxy-2-naphthyl)-3-hydroxybutan-2-one (3-hydroxy nabumetone) by gut microbiota through carbonyl reduction, which results in the decrease of the drug's activity. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7245). | |||
| REF 2 | ClinicalTrials.gov (NCT01164826) Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions. U.S. National Institutes of Health. | |||
| REF 3 | Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):317-26. | |||
| REF 4 | Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites. J Pharm Biomed Anal. 2013 Jun;80:164-72. | |||
| REF 5 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 6 | Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.